Sanofi (SNYNF)
| Previous Close | 99.00 |
| Open | 97.91 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 97.51 - 97.91 |
| 52 Week Range | 88.75 - 112.65 |
| Volume | 6,862 |
| Avg. Volume | 8,970 |
| Market Cap | 122.396B |
| Beta (5Y Monthly) | 0.41 |
| PE Ratio (TTM) | 18.16 |
| EPS (TTM) | 5.37 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.86 (3.90%) |
| Ex-Dividend Date | May 05, 2021 |
| 1y Target Est | N/A |
- GlobeNewswire
Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease Pivotal trial met primary and all key secondary endpointsDupixent significantly reduced itch at 12 weeks, and nearly three times as many Dupixent patients experienced reductions in both itch and skin lesions at 24 weeksData reinforce impact of targeting IL-4 and IL-13, key and central drivers of type 2 infl
- GlobeNewswire
FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma
FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option Only biologic medicine approved for children with oral corticosteroid-dependent asthmaData reinforce well-established safety profile of Dupixent PARIS and TARRYTOWN, N.Y. – October 20, 2021 - The U.S. Food and D
- Yahoo Finance Video
Doctor on Covid-19: ‘This is a virus that is really here to stay’
Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.
